Aberrant Drug-Related Behavior Observed During a 12-Week Open-Label Extension Period of a Study Involving Patients Taking Chronic Opioid Therapy for Persistent Pain and Fentanyl Buccal Tablet or Traditional Short-Acting Opioid for Breakthrough Pain

Passik, Steven D.; Narayana, Arvind; Yang, Ronghua

doi:10.1111/pme.12431

Cited by 34 publications

(30 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The correlation between these two content subscales was significant ( r =0.64, p <.001), although represented only 41% shared variance. The clinical cutoff on the SOAPP-R (total score of 18 or more) for identifying elevated opioid risk was exceeded by 25.5% of the sample, similar to prior work 34 .…”

Section: Resultssupporting

confidence: 73%

“…It has demonstrated good reliability, as well as validity for prediction of subsequent objective markers of opioid misuse, such as toxicology results and aberrant drug behaviors 9,10,26,32,34 . It is often used in clinical chronic pain management settings for purposes of opioid risk mitigation.…”

Section: Methodsmentioning

confidence: 99%

“…One of the most common is the Screener and Opioid Assessment for Patients with Pain-Revised (SOAPP-R), which is intended specifically for screening use in the chronic pain population 9,10 . There is evidence for the predictive validity of the SOAPP-R in the chronic pain management context 9,26,32,34 . For example, baseline SOAPP-R scores predicted subsequent aberrant drug behaviors in a clinical trial of opioid therapy in chronic pain patients 34 .…”

Section: Introductionmentioning

confidence: 99%

“…There is evidence for the predictive validity of the SOAPP-R in the chronic pain management context 9,26,32,34 . For example, baseline SOAPP-R scores predicted subsequent aberrant drug behaviors in a clinical trial of opioid therapy in chronic pain patients 34 .…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

The Contribution of Differential Opioid Responsiveness to Identification of Opioid Risk in Chronic Pain Patients

Bruehl

Burns

Passik

et al. 2015

The Journal of Pain

Self Cite

View full text Add to dashboard Cite

The Screener and Opioid Assessment for Patients with Pain-Revised (SOAPP-R) predicts increased risk of opioid misuse in chronic pain patients. We evaluated whether higher SOAPP-R scores are associated with greater opioid reinforcing properties, potentially contributing to their predictive utility. Across two counterbalanced laboratory sessions, 55 chronic low back pain sufferers completed the SOAPP-R at baseline, and measures of back pain intensity, evoked pain responsiveness (thermal, ischemic), and subjective opioid effects after receiving intravenous morphine (0.08 mg/kg) or saline placebo. Morphine effect measures were derived for all outcomes reflecting the difference between morphine and placebo condition values. Higher SOAPP-R scores were significantly associated with greater desire to take morphine again, less feeling down and feeling bad, and greater reductions in sensory low back pain intensity following morphine administration. This latter effect was due primarily to SOAPP-R content assessing medication-specific attitudes and behavior. Individuals exceeding the clinical cutoff (18 or more) on the SOAPP-R exhibited significantly greater morphine liking, desire to take morphine again, and feeling sedated; lower feeling bad; and greater reductions in sensory low back pain following morphine. The SOAPP-R may predict elevated opioid risk in part by tapping into individual differences in opioid reinforcing effects.

show abstract

Section: Resultssupporting

confidence: 73%

Section: Methodsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

The Contribution of Differential Opioid Responsiveness to Identification of Opioid Risk in Chronic Pain Patients

Bruehl

Burns

Passik

et al. 2015

The Journal of Pain

Self Cite

View full text Add to dashboard Cite

show abstract

“…SOAPP-R scores (range 0 to 96) have been predictive of subsequent aberrant drug related behaviors [36] thought to be related to the development of OUD. A score of 18 or greater has clinical utility in identifying at-risk patients [36].…”

Section: Methodsmentioning

confidence: 99%

Temporal preference in individuals reporting chronic pain: discounting of delayed pain-related and monetary outcomes

Tompkins

Johnson

Smith

et al. 2016

Pain

View full text Add to dashboard Cite

Opioid therapy for pain is associated with an increased risk for substance use disorders (SUD). This study’s purpose was to determine the association between opioid misuse propensity (Screener and Opioid Assessment for Patients in Pain-Revised; SOAPP-R) and delay discounting, a behavioral process linked to SUD which quantifies the extent to which outcomes are devalued due to their delay. Participants reporting chronic pain (PRCP N=249) answered pain and opioid use questions, and then completed four delay discounting tasks. Each of these tasks assessed either money or pain consequences, framed as either rewards or punishments. Each task involved hypothetical choices between immediate smaller vs. delayed larger consequences. The extant Monetary Choice Questionnaire (MCQ) assessed delay discounting of money rewards, and a modified version assessed discounting of money losses (immediate smaller loss vs. larger delayed loss). Based on the MCQ, the novel Pain Relief Choice Questionnaire (PRCQ) assessed choices between an immediate short duration of pain relief vs. a longer duration of pain relief. Similarly, the novel Additional Pain Choice Questionnaire (APCQ) assessed choices between an immediate short duration of additional pain vs. a longer duration of additional pain. Discounting of both additional pain and money losses were significantly associated with high SOAPP-R scores – indicating participants at greatest risk for opioid misuse discount future punishments rather than future rewards compared to those at low risk. Measures of delay discounting may have promise in more accurately identifying individuals at highest risk for opioid misuse during chronic opioid therapy.

show abstract

Oxycodone for cancer-related pain

Schmidt‐Hansen

Bennett

Arnold

et al. 2017

Cochrane Database of Systematic Reviews

View full text Add to dashboard Cite

, we found six more relevant studies. In total, we included 23 studies with 2648 participants. These studies compared the painkilling ability (benefit) and side effects (harms) of different types of oxycodone to each other or to other strong painkillers. Key results Generally, the studies showed that oxycodone is an equally effective strong painkiller whether taken every six or every hours, and equally effective as other strong pain killers, such as morphine. All the strong painkillers examined in the studies were also associated with a number of unwanted effects, such as vomiting, constipation, and drowsiness. Overall, these do not differ between oxycodone and the other strong painkillers. Hallucinations (where people experience imaginary things, e.g. hearing voices) are much less common as a side effect but we found that they were less likely with oxycodone than within morphine. Overall, we found that the current evidence is comprised of studies that contained small numbers of participants of which many (19%) did not complete the studies. However, since there was very little difference between oxycodone and morphine, more research in this area is unlikely. Studies looking at oxycodone compared to other strong pain killers may be useful. Quality of the evidence We rated the quality of the evidence from studies using four levels: very low, low, moderate, or high. Very low quality evidence means that we are very uncertain about the results. High quality evidence means that we are very confident in the results. Overall the quality of the evidence was low or very low, downgraded because of issues with study quality and size.

show abstract

Aberrant Drug-Related Behavior Observed During a 12-Week Open-Label Extension Period of a Study Involving Patients Taking Chronic Opioid Therapy for Persistent Pain and Fentanyl Buccal Tablet or Traditional Short-Acting Opioid for Breakthrough Pain

Abstract: Incidence of aberrant drug-related behaviors was similar between patients taking fentanyl buccal tablet and traditional short-acting opioids over 12 weeks.

Cited by 34 publications

References 21 publications

The Contribution of Differential Opioid Responsiveness to Identification of Opioid Risk in Chronic Pain Patients

The Contribution of Differential Opioid Responsiveness to Identification of Opioid Risk in Chronic Pain Patients

Temporal preference in individuals reporting chronic pain: discounting of delayed pain-related and monetary outcomes

Oxycodone for cancer-related pain

Contact Info

Product

Resources

About